Stand Up To Cancer - standup2cancer.orgThis is where the end of cancer begins
   Please leave this field empty

Press Releases

Share this:
Email

Like this page on Facebook


Fifth Third Surpasses $4M in Donations to SU2C; Commits to Further Collaboration in Multi-Year Deal

December 16, 2014 - Fifth Third Bank announced today that the Company has exceeded $4 million in donations to Stand Up To Cancer (SU2C) through contributions from its SU2C credit and debit cards as well as its 2014 “Pay to the Order of” campaign.

+ More



Stand Up To Cancer Supported Research Discovers Why Patients Respond to a Life-Saving Melanoma Drug

November 26, 2014 – Work supported by the Stand Up To Cancer (SU2C) – Cancer Research Institute (CRI) – Immunology Translational Research Dream Team, launched in 2012 to focus on how the patient’s own immune system can be harnessed to treat some cancers have pioneered an approach to predict why advanced melanoma patients respond to a new life-saving melanoma drug.

+ More



SU2C and the Dutch Cancer Society Form a Dream Team to Improve Early Detection of Colorectal Cancer

November 18, 2014 – Stand Up To Cancer (SU2C) and the Dutch Cancer Society, KWF Kankerbestrijding (KWF), along with the American Association for Cancer Research (AACR), SU2C’s Scientific Partner, announced today the formation of an international Dream Team of top research scientists with the goal of improving early detection of colorectal cancer, currently the world’s fourth-leading cause of cancer death.

+ More



Ken Burns’ “Cancer: The Emperor Of All Maladies” to Premiere on PBS March 30-April 1, 2015

November 10, 2014 - Ken Burns Presents CANCER: THE EMPEROR OF ALL MALADIES, a three-part, six-hour documentary directed by award-winning filmmaker Barak Goodman and executive produced by Ken Burns, will air on PBS March 30-April 1, 2015, WETA Washington, D.C. announced today.

+ More



SU2C Epigenetics Dream Team Continues With $7.5 Million Funding From Van Andel Research Institute

November 11, 2014 – The work of one of the Stand Up To Cancer (SU2C) inaugural Dream Teams, launched in 2009 to focus on epigenetic therapy in cancer treatment, will continue with the commitment of $7.5 million from Van Andel Research Institute (VARI). Peter A. Jones, PhD, DSc, VARI’s research director and chief scientific officer, and Stephen Baylin, MD, deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, will serve as leaders of the Dream Team.

+ More


Innovate Collaborate Accelerate
Cancer accounts for nearly 1 of every 4 deaths in the US.